White Anthony R, Ryoo Sungwoo, Li Dechun, Champion Hunter C, Steppan Jochen, Wang Danming, Nyhan Daniel, Shoukas Artin A, Hare Joshua M, Berkowitz Dan E
Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Hypertension. 2006 Feb;47(2):245-51. doi: 10.1161/01.HYP.0000198543.34502.d7. Epub 2005 Dec 27.
Arginase, expressed in endothelial cells and upregulated in aging blood vessels, competes with NO synthase (NOS) for l-arginine, thus modulating vasoreactivity and attenuating NO signaling. Moreover, arginase inhibition restores endothelial NOS signaling and l-arginine responsiveness in old rat aorta. The arginase isoform responsible for modulating NOS, however, remains unknown. Because isoform-specific arginase inhibitors are unavailable, we used an antisense (AS) oligonucleotide approach to knockdown arginase I (Arg I). Western blot and quantitative PCR confirmed that Arg I is the predominant isoform expressed in endothelialized aortic rings and is upregulated in old rats compared with young. Aortic rings from 22-month-old rats were incubated for 24 hours with sense (S), AS oligonucleotides, or medium alone (C). Immunohistochemistry, immunoblotting, and enzyme assay confirmed a significant knockdown of Arg I protein and arginase activity in AS but not S or C rings. Conversely, calcium-dependent NOS activity and vascular metabolites of NO was increased in AS versus S or C rings. Acetylcholine (endothelial-dependent) vasorelaxant responses were enhanced in AS versus S or C treated rings. In addition, 1H-oxadiazolo quinoxalin-1-one (10 micromol/L), a soluble guanylyl cyclase inhibitor, increased the phenylephrine response in AS compared with S and C rings suggesting increased NO bioavailability. Finally, l-arginine (0.1 mmol/L)-induced relaxation was increased in AS versus C rings. These data support our hypothesis that Arg I plays a critical role in the pathobiology of age-related endothelial dysfunction. AS oligonucleotides may, therefore, represent a novel therapeutic strategy against age-related vascular endothelial dysfunction.
精氨酸酶在内皮细胞中表达,且在衰老血管中上调,它与一氧化氮合酶(NOS)竞争L-精氨酸,从而调节血管反应性并减弱NO信号传导。此外,抑制精氨酸酶可恢复老年大鼠主动脉中的内皮型一氧化氮合酶信号传导和L-精氨酸反应性。然而,负责调节NOS的精氨酸酶同工型仍不清楚。由于缺乏同工型特异性精氨酸酶抑制剂,我们采用反义(AS)寡核苷酸方法来敲低精氨酸酶I(Arg I)。蛋白质免疫印迹和定量PCR证实,Arg I是在内皮化主动脉环中表达的主要同工型,与年轻大鼠相比,老年大鼠中其表达上调。将22月龄大鼠的主动脉环分别与正义(S)寡核苷酸、AS寡核苷酸或单独的培养基(C)孵育24小时。免疫组织化学、免疫印迹和酶测定证实,AS环中Arg I蛋白和精氨酸酶活性显著降低,而S环和C环则无此现象。相反,与S环或C环相比,AS环中钙依赖性NOS活性和NO的血管代谢产物增加。与S环或C环相比,AS处理的环中乙酰胆碱(内皮依赖性)血管舒张反应增强。此外,与S环和C环相比,可溶性鸟苷酸环化酶抑制剂1H-恶二唑并喹喔啉-1-酮(10 μmol/L)使AS环中去氧肾上腺素反应增强,提示NO生物利用度增加。最后,与C环相比,AS环中L-精氨酸(0.1 mmol/L)诱导的舒张增强。这些数据支持了我们的假设,即Arg I在年龄相关的内皮功能障碍的病理生物学中起关键作用。因此,AS寡核苷酸可能代表一种针对年龄相关血管内皮功能障碍的新型治疗策略。